2016
Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis
Smith PH, Weinberger AH, Zhang J, Emme E, Mazure CM, McKee SA. Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis. Nicotine & Tobacco Research 2016, 19: 273-281. PMID: 27613893, PMCID: PMC5939704, DOI: 10.1093/ntr/ntw144.Peer-Reviewed Original ResearchConceptsTransdermal nicotineSmoking cessationBupropion SRComparative efficacyFirst option treatmentSustained release bupropionPlacebo-controlled trialSex differencesCigarette smoking cessationNetwork Meta-AnalysisRelease bupropionCessation pharmacotherapyOption treatmentGeneral community sampleCigarette smokersQuit ratesVarenicline's efficacyPharmacological interventionsVareniclineBupropionNicotine addictionMeta-AnalysisPlaceboSimilar outcomesSignificant sex differences
2012
Two Decades of Smoking Cessation Treatment Research on Smokers with Depression: 1990–2010
Weinberger AH, Mazure CM, Morlett A, McKee SA. Two Decades of Smoking Cessation Treatment Research on Smokers with Depression: 1990–2010. Nicotine & Tobacco Research 2012, 15: 1014-1031. PMID: 23100459, PMCID: PMC3693502, DOI: 10.1093/ntr/nts213.Peer-Reviewed Original ResearchConceptsRelationship of depressionSmoking cessation outcomesCessation outcomesSmoking cessationTreatment outcomesCurrent major depressive disorderMajor depressive disorderCurrent depression symptomsClinical trialsDepressive disorderMinor depressionMajor depressionInclusion criteriaMEDLINE searchPast diagnosisTreatment approachesDepression symptomsHealth-related risksMajority of studiesPotential articlesDepressionRacial differencesOutcomesCessationSmokers
2010
Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion
Mazure CM, Toll B, McKee SA, Wu R, O’Malley S. Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug And Alcohol Dependence 2010, 114: 68-72. PMID: 20832955, PMCID: PMC3016455, DOI: 10.1016/j.drugalcdep.2010.07.024.Peer-Reviewed Original ResearchMeSH KeywordsAdultBupropionFemaleFollicular PhaseHumansLuteal PhaseMenstrual CycleSmokingSmoking CessationTime FactorsTreatment OutcomeConceptsMenstrual cycle phaseQuit datePoint prevalence abstinencePremenopausal womenBupropion SRFollicular phaseLuteal phaseAbsence of pharmacotherapySustained release bupropionOpen-label trialCycle phaseMechanism of actionRelease bupropionLabel trialNicotine replacementCessation interventionsOpen trialTreatment completionCessation outcomesContinuous abstinenceQuit dayGonadal hormonesTreatment periodAbstinence outcomesQuit attemptsExploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch
Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O’Malley S. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug And Alcohol Dependence 2010, 112: 1-8. PMID: 20561758, PMCID: PMC2946976, DOI: 10.1016/j.drugalcdep.2010.04.021.Peer-Reviewed Original ResearchConceptsPlacebo groupStudy completersNaltrexone doseClinical trialsContinuous abstinenceOral naltrexone treatmentNicotine patch therapyNicotine replacement therapyInteractive voice responseRandomized clinical trialsMenstrual cycle statusEffect of doseNaltrexone augmentationNaltrexone groupAdverse eventsNaltrexone treatmentNicotine patchPatch therapyReplacement therapyQuit dayWeek 1AbstinenceDoseWomenLess adherent
2008
Message Framing for Smoking Cessation: The Interaction of Risk Perceptions and Gender
Toll BA, Salovey P, O'Malley SS, Mazure CM, Latimer A, McKee SA. Message Framing for Smoking Cessation: The Interaction of Risk Perceptions and Gender. Nicotine & Tobacco Research 2008, 10: 195-200. PMID: 18188760, PMCID: PMC2527723, DOI: 10.1080/14622200701767803.Peer-Reviewed Original ResearchConceptsMessage framing interventionsRisk of cessationSmoking cessationLung cancerClinical trialsGain-framed messagesHigh riskSmoking relapseHealth message framingHealth problemsLoss-framed messagesSmokingFraming interventionCessationNumber of daysInfluence of genderInterventionRiskRisk perceptionWomenMedian splitGain-framed conditionDaysMenGender differences
2007
Depressive Symptoms and Sex Affect Completion Rates and Clinical Outcomes in Cardiac Rehabilitation
Caulin‐Glaser T, Maciejewski PK, Snow R, LaLonde M, Mazure C. Depressive Symptoms and Sex Affect Completion Rates and Clinical Outcomes in Cardiac Rehabilitation. Preventive Cardiology 2007, 10: 15-21. PMID: 17215628, DOI: 10.1111/j.1520-037.2007.05666.x.Peer-Reviewed Original ResearchConceptsBDI-II scoresClinical outcomesDepressive symptomsMultiple logistic regression analysisCardiac rehabilitation completionBody mass indexCoronary heart diseaseLogistic regression analysisSymptoms of depressionLower BDI-II scoresRehabilitation completionExercise capacityCardiac rehabilitationCardiovascular benefitsMass indexCR programCardiovascular healthHeart diseaseLipid profileSymptomsPatientsIndependent effectsWomenRegression analysisCompletion rates
2005
Perceived risks and benefits of smoking cessation: Gender-specific predictors of motivation and treatment outcome
McKee SA, O'Malley SS, Salovey P, Krishnan-Sarin S, Mazure CM. Perceived risks and benefits of smoking cessation: Gender-specific predictors of motivation and treatment outcome. Addictive Behaviors 2005, 30: 423-435. PMID: 15718060, DOI: 10.1016/j.addbeh.2004.05.027.Peer-Reviewed Original ResearchConceptsPretreatment motivationTreatment-seeking smokersSelf-report instrumentGood psychometric propertiesSmoking cessationGender-specific predictorsTreatment outcomesSmoking cessation trialLikelihood ratingsBehavioral intentionsPsychometric propertiesMotivationIntervention strategiesCessation trialGender differencesPublic education campaignsPrimary aimStrong associationBeliefsParticipantsRatingsIntentionOutcomesSubsampleEducation campaigns
2004
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study
Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry 2004, 55: 296-300. PMID: 14744472, DOI: 10.1016/j.biopsych.2003.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAdultAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicChromatography, High Pressure LiquidDepressive DisorderDesipramineDouble-Blind MethodDrug Therapy, CombinationFemaleFluoxetineHumansMaleMiddle AgedNorepinephrinePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSerotoninTreatment OutcomeConceptsMontgomery-Asberg Depression Rating ScaleHamilton Depression Rating Scale scoresDepression Rating Scale scoresNonpsychotic unipolar major depressionPatient withdrew consentTreatment-resistant patientsWeeks of hospitalizationWeeks of treatmentCombination of fluoxetineOnset of actionAdequate plasma levelsDouble-blind conditionsDepression Rating ScaleTreatment of depressionRating Scale scoresUnipolar major depressionDrug plasma concentrationsDMI doseWithdrew consentAntidepressant medicationRandomized studyReuptake inhibitionSerotonergic agentsPlasma levelsMajor depression
2001
Clozapine in the treatment of aggression in an adolescent with autistic disorder.
Chen N, Bedair H, McKay B, Bowers M, Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. The Journal Of Clinical Psychiatry 2001, 62: 479-80. PMID: 11465533, DOI: 10.4088/jcp.v62n0612h.Peer-Reviewed Original Research
2000
Adverse Life Events and Cognitive-Personality Characteristics in the Prediction of Major Depression and Antidepressant Response
Mazure CM, Bruce ML, Maciejewski PK, Jacobs SC. Adverse Life Events and Cognitive-Personality Characteristics in the Prediction of Major Depression and Antidepressant Response. American Journal Of Psychiatry 2000, 157: 896-903. PMID: 10831468, DOI: 10.1176/appi.ajp.157.6.896.Peer-Reviewed Original ResearchConceptsCognitive-personality stylesCognitive–personality characteristicsAdverse life eventsStressful life eventsMajor depressionLife eventsTreatment outcomesComparison subjectsDepressive onsetMultivariate modelCommunity comparison subjectsDSM-IV unipolar depressionDepressive symptom severityHealthy comparison subjectsEvent typesAntidepressant regimenAdverse eventsAntidepressant responseInterpersonal eventsAchievement eventsUnipolar depressionBetter outcomesEpisode onsetSymptom severityGroup status
1999
Olanzapine for Treatment-Refractory Psychosis in Patients Responsive to, but Intolerant of, Clozapine
Weiss E, Longhurst J, Bowers M, Mazure C. Olanzapine for Treatment-Refractory Psychosis in Patients Responsive to, but Intolerant of, Clozapine. Journal Of Clinical Psychopharmacology 1999, 19: 378-380.. PMID: 10440469, DOI: 10.1097/00004714-199908000-00017.Peer-Reviewed Original Research
1998
Acute Neuroleptic Treatment in Elderly Patients Without Dementia
Mazure C, Nelson J, Jatlow P, Bowers M. Acute Neuroleptic Treatment in Elderly Patients Without Dementia. American Journal Of Geriatric Psychiatry 1998, 6: 221-229. PMID: 9659955, DOI: 10.1097/00019442-199800630-00005.Peer-Reviewed Original ResearchConceptsNon-elderly adultsElderly patientsNeuroleptic treatmentAcute responseLow dosesLow-dose neuroleptic treatmentAcute neuroleptic treatmentAdverse effectsHigh-dose treatmentLow-dose treatmentDrug blood levelsPrimary psychotic illnessInitial doseBlood levelsPsychotic illnessEffective treatmentPatientsDose ratioLonger durationTreatmentLower ratesDosesAdultsResponseNeuroleptics
1995
Developmental and Biologic Correlates of Early Neuroleptic Response
Bowers M, Mazure C, Glick M, Zigler E. Developmental and Biologic Correlates of Early Neuroleptic Response. Journal Of Clinical Psychopharmacology 1995, 15: 224-225.. PMID: 7636003, DOI: 10.1097/00004714-199506000-00014.Peer-Reviewed Original ResearchDesipramine Treatment of Major Depression in Patients Over 75 Years of Age
Nelson J, Mazure C, Jatlow P. Desipramine Treatment of Major Depression in Patients Over 75 Years of Age. Journal Of Clinical Psychopharmacology 1995, 15: 99-105.. PMID: 7782495, DOI: 10.1097/00004714-199504000-00004.Peer-Reviewed Original ResearchConceptsYounger patientsYears of ageElderly patientsMajor depressionDesipramine concentrationsDrug treatmentPatient trialsAdverse reaction rateMore effective drug treatmentsEffective drug treatmentUnipolar major depressionDesipramine treatmentDepressed patientsComparable dosesPatientsSide effectsResponse rateSimilar durationTrialsSecond trialTreatmentLower ratesBloodDepressionAge
1994
Characteristics of desipramine-refractory depression.
Nelson JC, Mazure CM, Jatlow PI. Characteristics of desipramine-refractory depression. The Journal Of Clinical Psychiatry 1994, 55: 12-9. PMID: 8294386.Peer-Reviewed Original ResearchConceptsDepressive episodePoor responseMajor depressionNonpsychotic unipolar major depressionPrior treatment failureAdequate blood levelsWeeks of hospitalizationDrug responseUnipolar major depressionRecurrence of depressionDefinite personality disorderDiagnosis of melancholiaConsecutive inpatientsDesipramine levelsTreatment failureBlood levelsGeneral HospitalInitial severityPlasma concentrationsDrug treatmentSecondary depressionDepression InventoryPatientsPersonality disorderDepression
1993
Premorbid social competence and the effectiveness of early neuroleptic treatment
Glick M, Mazure C, Bowers M, Zigler E. Premorbid social competence and the effectiveness of early neuroleptic treatment. Comprehensive Psychiatry 1993, 34: 396-401. PMID: 7907536, DOI: 10.1016/0010-440x(93)90064-b.Peer-Reviewed Original Research